Heme and HO-1 inhibition of HCV, HBV, and HIV

Frontiers in Pharmacology

Volumn 3 OCT, Issue , 2012, Pages

  Schmidt, Warren N ^a   Mathahs, M Meleah ^a   Zhu, Zhaowen ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

Biliverdin; HBV; HCV; Heme; HIV; Metalloporphyrins; Proteases; Viruses

Indexed keywords

BILIRUBIN; BILIVERDIN; HEME; HEME OXYGENASE 1; INTERFERON; METALLOPORPHYRIN; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 4A; PORPHYRIN DERIVATIVE; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; DRUG EFFECT; DRUG MECHANISM; DRUG STRUCTURE; ENZYME INHIBITION; ENZYME STRUCTURE; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERFERON INDUCTION; MIXED INFECTION; NONHUMAN; PROTEIN EXPRESSION; REPLICON; VIRUS INDUCTION; VIRUS INHIBITION; VIRUS REPLICATION;

EID: 84866179947     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2012.00129     Document Type: Article

References (111)

1. Abdalla, M. Y., Britigan, B. E., Wen, E, Icardi, M., McCormick, M. L., LaBrecque, D. R., Voigt, M., Brown, K. E., and Schmidt, W. N. (2004). Down-regulation of heme oxygenase-1 by hepatitis C virus infection in vivo and by the in vitro expression of hepatitis C core protein. J. Infect. Dis. 190, 1109-1118.
2. Abraham, N. G., Lavrovsky, Y., Schwartzman, M. L., Stoltz, R. A., Levere, R. D., Gerritsen, M. E., Shibahara, S., and Kappas, A. (1995). Transfection of the human heme oxygenase gene into rabbit coronary microvessel endothelial-cells - protective effect against heme and hemoglobin toxicity. Proc. Natl. Acad. Sci. U.S.A. 92,6798-6802.
3. Argyris, E. G., Vanderkooi, J. M., Venkateswaran, P. S., Kay, B. K., and Paterson, Y. (1999). The connectiondomain is implicated in metallopor-phyrin binding and inhibition of HIV reverse transcriptase. J. Biol. Chem. 274,1549-1556.
4. Barresinoussi, F., Chermann, J. C., Rey, E, Nugeyre, M. T., Chamaret, S., Gruest, J., Dauguet, C., Axlerblin, C., Vezinetbrun, F., Rouzioux, C., Rozenbaum, W., and Montagnier, L. (1983). Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune-deficiency syndrome (AIDS). Science 220,868-871.
5. Bauer, I., Rensing, H., Florax, A., Ulrich, C., Pistorius, G., Redl, H., and Bauer, M. (2003). Expression pattern and regulation of heme oxygenase-1 heat shock protein 32 in human liver cells. Shock 20,116-122.
6. Beinker, N. K., Voigt, M. D., Arendse, M., Smit, J., Stander, I. A., and Kirsch, R. E. (1996). Threshold effect of liveriron content on hepatic inflammation and fibrosis in hepatitis B and C. J. Hepatol. 25, 633-638.
7. Benzaghou, I., Bougie, I., and Bisaillon, M. (2004). Effect of metal ion binding on the structural stability of the hepatitis C virus RNA polymerase. J. Biol. Chem. 279,49755-49761.
8. Bissig, K. D., Le, T. T., Woods, N. B., and Verma, I. M. (2007). Repopu-lation of adult and neonatal mice with human hepatocytes: a chimeric animal model. Proc. Natl. Acad. Sci. U.S.A. 104,20507-20511.
9. Bissig, K. D., Wieland, S. F., Tran, P., Isogawa, M., Le, T. T., Chisari, E V., and Verma, I. M. (2010). Human liver chimeric mice provide a model for hepatitis B and C virus infection and treatment. J. Clin. Invest. 120, 924-930.
10. Blight, K. J., McKeating, J. A., and Rice, C. M. (2002). Highly permissive celllines for subgenomic and genomic hepatitis C virus RNA replication. J. Virol. 76, 13001-13014.
11. Bode, J. G., Brenndorfer, E. D., and Haussinger, D. (2007). Subversion of innate host antiviral strategies by the hepatitis C virus. Arch. Biochem. Biophys. 462,254-265.
12. Bougie, I., Charpentier, S., and Bisaillon, M. (2003). Characterization of the metal ion binding properties of the hepatitis C virus RNA polymerase. J. Biol. Chem. 278, 3868-3875.
13. Brik, A., and Wong, C. H. (2003). HIV-1 protease: mechanism and drug discovery. Org. Biomol Chem. 1, 5-14.
14. Cai,Z. H.,Zhang, C., Chang, K. S.,Jiang, J. Y., Ahn, B. C., Wakita, T., Liang, T. J., and Luo, G. X. (2005). Robust production of infectious hepatitis C virus (HCV) from stably HCV cDNA-transfected human hepatoma cells.J. Virol. 79, 13963-13973.
15. Casteel, M. J., Jayaraj, K., Gold, A., Ball, L. M., and Sobsey, M. D. (2004). Photoinactivation of hepatitis A virus by synthetic porphyrins. Photochem. Photobiol. 80, 294-300.
16. Castet, V., Fournier, C., Soulier, A., Brillet, R., Coste, J., Larrey, D., Dhumeaux, D., Maurel, P., and Pawlotsky, J. M. (2002). Alpha inter-feron inhibits hepatitis C virus replication in primary human hepato-cytes infected in vitro. J. Virol. 76, 8189-8199.
17. Cheng, G., Zhong, J., Chung, J., and Chisari, E V. (2007). Double-stranded DNA and double-stranded RNA induce a common antiviral signaling pathway in human cells. Proc. Natl. Acad. Sci. U.S.A. 104, 9035-9040.
18. Cheng, Y., Tsou, L. K., Cai, J., Aya, T., Dutschman, G. E., Gullen, E. A., Grill, S. P., Chen, A. P., Linden-bach, B. D., Hamilton, A. D., and Cheng, Y. C. (2010). A novel class of meso-tetrakis-porphyrin derivatives exhibits potent activities against hepatitis C virus genotype 1b repli-cons in vitro. Antimicrob. Agents Chemother. 54, 197-206.
19. Cruse, I., and Maines, M. D. (1988). Evidence suggesting that the two forms of heme oxygenase are products of different genes. J. Biol. Chem. 263, 3348-3353.
20. Darby, S. C., Ewart, D. W., Giangrande, P. L. F., Spooner, R. J. D., Rizza, C. R., Dusheiko, G. M., Lee, C. A., Lud-lam, C. A., and Preston, E E. (1997). Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C. Lancet 350, 1425-1431.
21. De Clercq, E. (2007). The design of drugs for HIV and HCV. Nat. Rev. DrugDiscov. 6, 1001-1018.
22. de Jong, Y. P., Rice, C. M., and Ploss, A. (2010). New horizons for studying human hepatotropic infections. J. Clin. Invest. 120, 650-653.
23. Debnath, A. K., Jiang, S., Strick, N., Lin, K., Haberfield, P., and Neurath, A. R. (1994). 3-Dimensional structure-activity analysis of a series of por-phyrin derivatives with anti-HIV-1 activity targeted to the V3 loop of the gp120 envelope glycoprotein of the human-immunodeficiency-virus type-1. J. Med. Chem. 37, 1099-1108.
24. Debnath, A. K., Jiang, S. B., Strick, N., Lin, K., Kahl, S. B., and Neurath, A. R. (1999). Anti-HIV-1 activity of carborane derivatives of porphyrins. Med. Chem. Res. 9, 267-275.
25. Decamp, D. L., Babe, L. M., Salto, R., Lucich, J. L., Koo, M. S., Kahl,S. B., and Craik, C. S. (1992). Specific-inhibition of HIV-1 protease by boronated porphyrins. J. Med. Chem. 35, 3426-3428.
26. den Brinker, M., Wit, E W. N. M., Wertheim-van Dillen, P. M. E., Jur-riaans, S., Weel, J., van Leeuwen, R., Pakker, N. G., Reiss, P., Danner, S. A., Weverling, G. J., and Lange, J. M. A. (2000). Hepatitis B and C virus co-infection and the risk for hepato-toxicity of highly active antiretrovi-ral therapy in HIV-1 infection. AIDS 14,2895-2902.
27. Desai, T. K., Jamil, L. H., Balasubrama-niam, M., Koff, R., and Bonkovsky, H. L. (2008). Phlebotomy improves therapeutic response to interferon in patients with chronic hepatitis C: a meta-analysis of six prospective randomized controlled trials. Dig. Dis. Sci. 53,815-822.
28. Devadas, K., and Dhawan, S. (2006). Hemin activation ameliorates HIV-1 infection via heme oxygenase-1 induction. J. Immunol. 176, 4252-4257.
29. Di Bisceglie, A. M., Bonkovsky, H. L., Chopra, S., Flamm, S., Reddy, R. K., Grace, N., Killenberg, P., Hunt, C., Tamburro, C., Tavill, A. S., Ferguson, R., Krawitt, E., Banner, B., and Bacon, B. R. (2000). Iron reduction as an adjuvant to interferon therapy in patients with chronic hepatitis C who have previously not responded to interferon: a multicenter, prospective, randomized, controlled trial. Hepatology 32,135-138.
30. Ferrari, E., Wright-Minogue, J., Fang, J. W. S., Baroudy, B. M., Lau, J. Y. N., and Hong, Z. (1999). Characterization of soluble hepatitis C virus RNA-dependent RNA poly-merase expressed in Escherichia coli. J. Virol. 73, 1649-1654.
31. Fillebeen, C., Muckenthaler, M., Andricipoulos, B., Bisaillon, M., Mounir, Z., Hentze, M. W., Koromi-las, A. E., and Pantopoulos, K. (2007). Expression of the subge-nomic hepatitis C virus replicon alters iron homeostasis in Huh7 cells. J. Hepatol. 47, 12-22.
32. Fillebeen, C., Rivas-Estilla, A. M., Bisaillon, M., Ponka, P., Muckenthaler, M., Hentze, M. W., Koromilas, A. E., and Pantopoulos, K. (2005). Iron inactivates the RNA polymerase NS5B and suppresses subgenomic replication of hepatitis C Virus. J. Biol Chem. 280, 9049-9057.
33. Firpi, R. J., and Nelson, D. R. (2007). Current and future hepatitis C therapies. Arch. Med. Res. 38, 678-690.
34. Fontana, R. J., Israel, J., LeClair, P., Banner, B. F., Tortorelli, K., Grace, N., Levine, R. A., Fiarman, G., Thiim,M., Tavill, A. S., and Bonkovsky, H. L. (2000). Iron reduction before and during interferon therapy of chronic hepatitis C: results of a multicenter, randomized, controlled trial. Hepatology 31,730-736.
35. Gibbs, P. E., and Maines, M. D. (2007). Biliverdin inhibits activation of NF-kappaB: reversal of inhibition by human biliverdin reductase. Int. J. Cancer 121,2567-2574.
36. Gibbs, P. E. M., Miralem, T., and Maines, M. D. (2010). Characterization of the human biliverdin reductase gene structure and regulatory elements: promoter activity is enhanced by hypoxia and suppressed by TNF-alpha-activated NF-kappa B. FASEB J. 24, 3239-3254.
37. Gondeau, C., Pichard-Garcia, L., and Maurel, P. (2009). Cellular models for the screening and development of anti-hepatitis C virus agents. Pharmacol. Ther. 124,1-22.
38. Gozzelino, R., Jeney, V., and Soares, M. P. (2010). Mechanisms of cell protection by heme oxygenase-1. Annu. Rev. Pharmacol. 50, 323-354.
39. Gray, H. B., and Winkler, J. R. (1996). Electron transfer in proteins. Annu. Rev. Biochem. 65,537-561.
40. Guo, H. T., Pan, X. B., Mao, R. C., Zhang, X. C., Wang, L. J., Lu, X. Y., Chang, J. H., Guo, J. T., Passic, S., Krebs, E C., Wigdahl, B., Warren, T. K., Retterer, C. J., Bavari, S., Xu, X. D., Cuconati, A., and Block, T. M. (2011). Alkylated porphyrins have broad antiviral activity against hepad-naviruses, flaviviruses, filoviruses, and arenaviruses. Antimicrob. Agents Chemother. 55, 478-486.
41. Guo, X., Shin, V Y, and Cho, C. H. (2001). Modulation of heme oxygenase in tissue injury and its implication in protection against gastrointestinal diseases. Life Sci. 69, 3113-3119.
42. Hayashi, S., Omata, Y., Sakamoto, H., Higashimoto, Y., Hara, T., Sagara, Y., and Noguchi, M. (2004). Characterization of rat heme oxygenase-3 gene. Implication of processed pseudo-genes derived from heme oxygenase-2 gene. Gene 336, 241-250.
43. Heinemann, I. U., Jahn, M., and Jahn, D. (2008). The biochemistry of heme biosynthesis. Arch. Biochem. Bio-phys. 474, 238-251.
44. Hou, W., Tian, Q., Zheng, J., and Bonkovsky, H. L. (2010). Zinc mesoporphyrin induces rapid pro-teasomal degradation of hepatitis C nonstructural 5A protein in human hepatoma cells. Gastroen-terology 138, 1909-1919.
45. Hou, W. H., Rossi, L., Shan, Y., Zheng, J. Y., Lambrecht, R. W.,and Bonkovsky, H. L. (2009). Iron increases HMOX1 and decreases hepatitis C viral expression in HCV-expressing cells. World J. Gastroen-terol. 15,4499-4510.
46. Hou, W H., Shan, Y., Zheng, J. Y., Larnbrecht, R. W., Donohue, S. E., and Bonkovsky, H. L. (2008). Zinc mesoporphyrin induces rapid and marked degradation of the transcription factor Bach1 and up-regulates HO-1. Biochim. Biophys. Acta 1779, 195-203.
47. Immenschuh, S., and Ramadori, G. (2000). Gene regulation of heme oxygenase-1 as a therapeutic target. Biochem. Pharmacol. 60,1121-1128.
48. Kalliolias, G. D., and Ivashkiv, L. B. (2010). Overview of the biology of type I interferons. Arthritis Res. Ther. 12(Suppl. 1), S1.
49. Kapitulnik, J., and Maines, M. D. (2009). Pleiotropic functions of biliverdin reductase: cellular signaling and generation of cytoprotective and cyto-toxic bilirubin. Trends Pharmacol. Sci. 30, 129-137.
50. Kato, T., Date, T., Miyamoto, M., Furusaka, A., Tokushige, K., Mizokami, M., and Wakita, T. (2003). Efficient replication of the genotype 2a hepatitis C virus subgenomic replicon. Gastroenterology 125, 1808-1817.
51. Kayali, Z., Ranguelov, R., Mitros, F., Shufelt, C., Elmi, F., Rayhill, S. C., Schmidt, W N., and Brown, K. E. (2005). Hemosiderosis is associated with accelerated decompensation and decreased survival in patients with cirrhosis. Liver Int. 25, 41-48.
52. Kayali, Z., Tan, S., Shinkunas, L., Voigt, M., LaBrecque, D. R., Stapleton, J. T., Brown, K. E., and Schmidt, W. N. (2007). Risk factors for hepatitis C fibrosis: a prospective study of United States veterans compared with nonveterans.J. Viral Hepat. 14, 11-21.
53. Khvalevsky, E., Rivkin, L., Rachmilewitz, J., Galun, E., and Giladi, H. (2007). TLR3 signaling in a hepatoma cell line is skewed towards apoptosis. J. Cell Biochem. 100, 1301-1312.
54. Kitamuro, T., Takahashi, K., Ogawa, K., Udono-Fujimori, R., Takeda, K., Furuyama, K., Nakayama, M., Sun, J. Y., Fujita, H., Hida, W., Hattori, T., Shirato, K., Igarashi, K., and Shibahara, S. (2003). Bach1 functions as a hypoxia-inducible repres-sor for the heme oxygenase-1 gene in human cells. J. Biol Chem. 278, 9125-9133.
55. Koliaraki, V., and Kollias, G. (2011). A new role for myeloid HO-1 in the innate to adaptive crosstalkand immune homeostasis. Adv. Exp. Med.Biol. 780, 101-111.
56. Koziel, M. J., and Peters, M. G. (2007). Viral hepatitis in HIV infection. N. Engl. I Med. 356, 1445-1454.
57. Labbe, R. F. (1992). Clinical utility of zinc protoporphyrin. Clin. Chem. 38,2167-2168.
58. Lee, P. J., Alam, J., Wiegand, G. W., and Choi, A. M. K. (1996). Overexpres-sion of heme oxygenase-1 in human pulmonary epithelial cells results in cell growth arrest and increased resistance to hyperoxia. Proc. Natl. Acad. Sci. U.S.A. 93,10393-10398.
59. Lee, Y. I., Hwang, J. M., Im, J. H., Lee, Y. I., Kim, N. S., Kim, D. G., Yu, D. Y., Moon, H. B., and Park, S. K. (2004). Human hepatitis B virus-X protein alters mitochon-drial function and physiology in human liver cells. J. Biol. Chem. 279, 15460-15471.
60. Lehmann, E., El-Tantawy, W. H., Ocker, M., Bartenschlager, R., Lohmann, V., Hashemolhosseini, S., Tiegs, G., and Sass, G. (2010). The heme oxyge-nase 1 product biliverdin interferes with hepatitis C virus replication by increasing antiviral interferon response. Hepatology 51, 398-404.
61. Lemon, S. M., Murphy, P. C., Smith, A., Zou, J. S., Hammon, J., Robinson, S., and Horowitz, B. (1994). Removal/neutralization of hepatitis-a virus during manufacture of high-purity, solvent/detergent factor-Viii concentrate. J. Med. Virol. 43, 44-49.
62. Levere, R. D., Gong, Y. F., Kappas, A., Bucher, D. J., Wormser, G. P., and Abraham, N. G. (1991). Heme inhibits human immunodeficiency virus 1 replication in cell cultures and enhances the antiviral effect of zidovudine. Proc. Natl. Acad. Sci. U.S.A. 88, 1756-1759.
63. Li, K., Chen, Z. H., Kato, N., Gale, M., and Lemon, S. M. (2005a). Distinct poly (I-C) and virus-activated signaling pathways leading to interferon-beta production in hepatocytes. J. Biol. Chem. 280, 16739-16747.
64. Li, K., Foy, E., Ferreon, J. C., Naka-mura, M., Ferreon, A. C. M., Ikeda, M., Ray, S. C., Gale, M., and Lemon, S. M. (2005b). Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF. Proc. Natl. Acad. Sci. U.S.A. 102, 2992-2997.
65. Lieber, C. S. (1997). Role of oxida-tive stress and antioxidant therapy in alcoholic and nonalcoholic liver diseases. Adv. Pharmacol. 38, 601-628.
66. Lin, L., and Hu, J. (2008). Inhibition of hepadnavirus reverse transcriptase-epsilon RNA interaction by por-phyrin compounds. J. Virol. 82, 2305-2312.
67. Lindenbach, B. D., and Rice, C. M. (2005). Unravelling hepatitis C virus replication from genome to function. Nature 436, 933-938.
68. Lohmann, V., Korner, F., Koch, J. O., Herian, U., Theilmann, L., and Bartenschlager, R. (1999). Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 285, 110-113.
69. Loo, Y M., Owen, D. M., Li, K., Erick-son, A. K., Johnson, C. L., Fish, P. M., Carney, D. S., Wang, T., Ishida, H., Yoneyama, M., Fujita, T., Saito, T., Lee, W. M., Hagedorn, C. H., Lau, D. T., Weinman, S. A., Lemon, S. M., and Gale, M. Jr. (2006). Viral and therapeutic control of IFN-beta promoter stimulator 1 during hepatitis C virus infection. Proc. Natl. Acad. Sci. U.S.A. 103,6001-6006.
70. Love, R. A., Parge, H. E., Wickersham, J. A., Hostomsky, Z., Habuka, N., Moomaw, E. W., Adachi, T., and Hos-tomska, Z. (1996). The crystal structure of hepatitis C virus NS3 pro-teinase reveals a trypsin-like fold and a structural zinc binding site. Cell 87, 331-342.
71. Makino, N., Suematsu, M., Sugiura, Y., Morikawa, H., Shiomi, S., Goda, N., Sano, T., Nimura, Y., Sugimachi, K., and Ishimura, Y. (2001). Altered expression of heme oxygenase-1 in the livers of patients with portal hypertensive diseases. Hepatology 33, 32-42.
72. McCoubrey, W. K., Huang, T. J., and Maines, M. D. (1997). Heme oxygenase-2 is a hemoprotein and binds heme through heme regulatory motifs that are not involved in heme catalysis. J. Biol. Chem. 272, 12568-12574.
73. McDonagh, A. F. (2001). Turning green to gold. Nat. Struct. Biol. 8,198-200.
74. McPhee, F., Caldera, P. S., Bemis, G. W., McDonagh, A. F., Kuntz, I. D., and Craik, C. S. (1996). Bile pigments as HIV-1 protease inhibitors and their effects on HIV-1 viral maturation and infectivity in vitro. Biochem. J. 320,681-686.
75. Mense, S. M., and Zhang, L. (2006). Herne: a versatile signaling molecule controlling the activities of diverse regulators ranging from transcription factors to MAP kinases. Cell Res. 16,681-692.
76. Meylan, E., Curran, J., Hofmann, K., Moradpour, D., Binder, M., Bartenschlager, R., and Tschopp, R. (2005). Cardif is an adaptor protein in theRIG-I antiviral pathway and is targeted by hepatitis C virus. Nature 437,1167-1172.
77. Nogales, D., and Lightner, D. A. (1995). On the structure of bilirubin in solution - C-13 (H-1) heteronu-clear Overhauser effect NMR analyses in aqueous buffer and organic-solvents. J. Biol. Chem. 270, 73-77.
78. Ogawa, K., Sun, J., Taketani, S., Naka-jima, O., Nishitani, C., Sassa, S., Hayashi, N., Yamamoto, M., Shiba-hara, S., Fujita, H., and Igarashi, K. (2001). Heme mediates derepres-sion of Maf recognition element through direct binding to transcription repressor Bach1. EMBO J. 20, 2835-2843.
79. Ollinger, R., Wang, H., Yamashita, K., Wegiel, B., Thomas, M., Margre-iter, R., and Bach, E H. (2007). Therapeutic applications of bilirubin and biliverdin in transplantation. Antioxid. Redox Signal. 9, 2175-2185.
80. Pietschmann, T., Lohmann, V., Rut-ter, G., Kurpanek, K., and Barten-schlager,R. (2001). Characterization of cell lines carrying self-replicating hepatitis C virus RNAs. J. Virol. 75, 1252-1264.
81. Pollack, J. R., and Ganem, D. (1994). Site-specific RNA-binding by a hepatitis-B virus reverse-transcriptase initiates 2 distinct reactions - RNA packaging and DNA-synthesis. J. Virol. 68, 5579-5587.
82. Popovic, M., Sarngadharan, M. G., Read, E., and Gallo, R. C. (1984). Detection, isolation, and continuous production of cytopathic retro-viruses (HTLV-III) from patients with AIDS and pre-AIDS. Science 224,497-500.
83. Protzer, U., Seyfried, S., Quasdorff, M., Sass, G., Svorcova, M., Webb, D., Bohne, F., Hosel, M., Schirmacher, P., and Tiegs, G. (2007). Antiviral activity and hepatoprotection by heme oxygenase-1 in hepatitis B virus infection. Gastroenterology 133,1156-1165.
84. Qadri, I., Iwahashi, M., Capasso, J. M., Hopken, M. W., Flores, S., Schaack, J., and Simon, E R. (2004). Induced oxidative stress and activated expression of manganese superoxide dismutase during hepatitis C virus replication: role of JNK, p38 MAR and AP-1. Biochem.J. 378, 919-928.
85. Qin,X. (2007). Inactivation of digestive proteases by deconjugated bilirubin: the possible evolutionary driving force for bilirubin or biliverdin predominance in animals. Gut 56, 1641-1642.
86. Quan, C. M., Krajden, M., Grigoriew, G. A., and Salit, I. E. (1993). Hepatitis-C virus-infection in patients infected with the human-immunodeficiency-virus Clin. Infect. Dis. 17, 117-119.
87. Ryter, S. W., Alam, J., and Choi, A. M. K. (2006). Heme oxygenase-1/carbon monoxide: from basic science to therapeutic applications. Physiol. Rev. 86, 583-650.
88. Ryter, S. W., and Tyrrell, R. M. (2000). The Heme synthesis and degradation pathways: role in oxidant sensitivity - heme oxygenase has both pro- and antioxidant properties. Free Radic. Biol. Med. 28, 289-309.
89. Seronello, S., Sheikh, M. Y., and Choi, J. (2007). Redox regulation of hepatitis C in nonalcoholic and alcoholic liver. Free Radic. Biol. Med. 43, 869-882.
90. Shan, Y., Zheng, J., Lambrecht, R. W., and Bonkovsky, H. L. (2007). Reciprocal effects of micro-RNA-122 on expression of heme oxygenase-1 and hepatitis C virus genes in human hepatocytes. Gastroenterology 133, 1166-1174.
91. Song, R., Witvrouw, M., Schols, D., Robert, A., Balzarini, J., DeClercq, E., Bernadou, J.,andMeunier,B. (1997). Anti-HIV activities of anionic met-alloporphyrins and related compounds. Antivir. Chem. Chemother. 8, 85-97.
92. Soriano, V., Peters, M. G., and Zeuzem, S. (2009). New therapies for hepatitis C virus infection. Clin. Infect. Dis. 48,313-320.
93. Staudinger, R., Abraham, N. G., Levere, R. D., and Kappas, A. (1996). Inhibition of human immunodeficiency virus-1 reverse transcrip-tase by heme and synthetic heme analogs. Proc. Assoc. Am. Physicians 108, 47-54.
94. Stojiljkovic, I., Evavold, B. D., and Kumar, V (2001). Antimicrobial properties of porphyrins. Expert Opin. Investig. Drugs 10, 309-320.
95. Tavis, J. E., Perri, S., and Ganem, D. (1994). Hepadnavirus reverse transcription initiates within the stem-loop of the RNA packaging signal and employs a novel strand transfer. J. Virol. 68, 3536-3543.
96. Telfer, P., Sabin, C., Devereux, H., Scott, E, Dusheiko, G., and Lee, C. (1994). The progression of HCV-associated liver-disease in a cohort of hemo-philic patients. Br. J. Haematol. 87, 555-561.
97. Tsutsui, K., and Mueller, G. C. (1987). Hemin inhibits virion-associated reverse-transcriptase of murine leukemia-virus. Biochem. Biophys. Res. Commun. 149, 628-634.
98. Tzima, S., Victoratos, P., Kranidioti, K., Alexiou, M., and Kollias, G. (2009). Myeloid heme oxygenase-1 regulates innate immunity and autoimmunity by modulating IFN-beta production.J. Exp. Med. 206, 1167-1179.
99. Wakita, T., Pietschmann, T., Kato, T., Date, T., Miyamoto, M., Zhao, Z. J., Murthy, K., Habermann, A., Kraus-slich, H. G., Mizokami, M., Barten-schlager, R., and Liang, T. J. (2005). Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat. Med. 11, 791-796.
100. Wang, G. H., Zoulim, F., Leber, E. H., Kitson, J., and Seeger, C. (1994). Role of RNA in enzymatic-activity of the reverse-transcriptase of hepatitis-B viruses. J. Virol. 68, 8437-8442.
101. Washburn, M. L., Bility, M. T., Zhang, L. G., Kovalev, G. I., Buntzman, A., Frelinger, J. A., Barry, W., Ploss, A., Rice, C. M., and Su, L. S. (2011). A humanized mouse model to study hepatitis C virus infection, immune response, and liver disease. Gastroen-terology 140, 1334-1344.
102. Wlodawer, A., Miller, M., Jaskolski, M., Sathyanarayana, B. K., Baldwin, E., Weber, I. T., Selk, L. M., Clawson,L., Schneider, J., and Kent, S. B. H. (1989). Conserved folding in retro-viral proteases - crystal-structure of a synthetic HIV-1 protease. Science 245,616-621.
103. Yan, Y. W., Li, Y., Munshi, S., Sardana, V., Cole, J. L., Sardana, M., Steinkuehler, C., Tomei, L., De Francesco, R., Kuo, L. C., and Chen, Z. G. (1998). Complex of NS3 protease and NS4A pep-tide of BK strain hepatitis C virus: A 2.2 angstrom resolution structure in a hexagonal crystal form. Protein Sci. 7, 837-847.
104. Yuasa, K., Naganuma, A., Sato, K., Ikeda, M., Kato, N., Takagi, H., and Mori, M. (2006). Zinc is a negative regulator of hepatitis C virus RNA replication. Liver Int. 26, 1111-1118.
105. Zhou, Y H., Liu, E L., Yao, Z. H., Duo, L., Li, H., Sun, Y., and Zheng, Y T. (2011). Comparison of HIV-, HBV-, HCV- and co-infection prevalence between Chinese and Burmese intravenous drug users of the China-Myanmar border region. PLoS ONE 6, e16349. doi:10.1371/journal.pone.00 16349
106. Zhu, Z., Wilson, A. T., Luxon, B. A., Brown, K. E., Mathahs, M. M., Bandyopadhyay, S., McCaffrey, A.P., and Schmidt, W. N. (2010a). Biliverdin inhibits hepatitis C virus nonstructural 3/4A protease activity: mechanism for the antiviral effects of heme oxygenase? Hepatology 52, 1897-1905.
107. Zhu, Z. W., Wilson, A. T., Gopalakr-ishna, K., Brown, K. E., Luxon, B. A., and Schmidt, W. N. (2010b). Hepatitis C virus core protein enhances telomerase activity in Huh7 cells. J. Med. Virol. 82, 239-248.
108. Zhu, Z., Wilson, A. T., Mathahs, M. M., Wen, F., Brown, K. E., Luxon, B. A., and Schmidt, W. N. (2008). Heme oxygenase-1 suppresses hepatitis C virus replication and increases resistance of hepatocytes to oxidant injury. Hepatology 48, 1430-1439.
109. Zhu, Z. W., Mathahs, M. M., and Schmidt, W. N. (2011). Biliverdin and heme restore type I inter-feron expression in cells expressing HCV NS3/4a protease. Hepatology 54, 541a.
110. Zoulim, E (2011). Hepatitis B virus resistance to antiviral drugs: where are we going? Liver Int. 31,111-116.
111. Zylberberg, H., and Pol, S. (1996). Reciprocal interactions between humanimmunodeficiency virus and hepatitis C virus infections. Clin. Infect. Dis. 23, 1117-1125.